<DOC>
	<DOCNO>NCT01193842</DOCNO>
	<brief_summary>This partially randomized phase I/II trial study side effect best dose vorinostat give together combination chemotherapy rituximab see well work compare combination chemotherapy alone treat patient human immunodeficiency virus-related diffuse large B-cell non-Hodgkin lymphoma aggressive B-cell lymphoma . Vorinostat may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Monoclonal antibody , rituximab , may interfere ability cancer cell grow spread . Giving vorinostat together combination chemotherapy rituximab may kill cancer cell .</brief_summary>
	<brief_title>Vorinostat Combination Chemotherapy With Rituximab Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma Other Aggressive B-Cell Lymphomas</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine recommend phase II dose ( RPTD ) vorinostat may use combination dose-adjusted etoposide , prednisone , vincristine sulfate , cyclophosphamide , doxorubicin hydrochloride rituximab ( R-DA-EPOCH ) ( high-risk disease ) participants human immunodeficiency virus ( HIV ) -associated aggressive cluster differentiation ( CD ) 20 positive non-Hodgkin lymphoma ( NHL ) . ( Phase I ) II . Determine overall toxicity rate R-DA-EPOCH ( high-risk disease ) without vorinostat . ( Phase II ) III . Determine efficacy combination R-DA-EPOCH ( high-risk disease ) without vorinostat HIV-associated aggressive CD20 positive NHL use complete response ( CR ) rate study endpoint . ( Phase II ) SECONDARY OBJECTIVES : I . Determine 1-year event-free survival ( EFS ) 1 year overall survival ( OS ) . II . Assess effect vorinostat chemotherapy latent HIV memory T cell . III . Assess effect vorinostat and/or chemotherapy HIV , Epstein-Barr virus ( EBV ) , human herpes virus 8 ( HHV-8 ) viral load bank specimen . IV . Assess effect vorinostat and/or chemotherapy T-cell subset ( CD4 CD8 ) plasma immunoglobulin level . V. Assess effect concurrent vorinostat rituximab plasma steady-state concentration etoposide , doxorubicin ( doxorubicin hydrochloride ) , vincristine ( vincristine sulfate ) ( Phase I ) . VI . Perform wide human gene expression profile methylation study tumor bank baseline . VII . Evaluate EBV HHV-8 gene expression pattern positive tumor bank baseline . OUTLINE : This phase I , dose-escalation study vorinostat follow phase II study . PHASE I : Patients receive vorinostat orally ( PO ) daily ( QD ) day 1-5 ; rituximab intravenously ( IV ) day 1 ; etoposide IV 24 hour , doxorubicin hydrochloride IV 24 hour , vincristine sulfate IV 24 hour day 1-4 ; prednisone PO daily day 1-5 ; cyclophosphamide IV 1 hour day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . PHASE II : Patients randomize 1 2 treatment arm . ARM A ( VR-DA-EPOCH ) : Patients receive vorinostat , rituximab , etoposide , doxorubicin hydrochloride , vincristine sulfate , prednisone , cyclophosphamide Phase I . ARM B ( DA-R-EPOCH ) : Patients receive rituximab , etoposide , doxorubicin hydrochloride , vincristine sulfate , prednisone , cyclophosphamide Arm A . In arm , treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion study therapy , patient follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Primary Effusion</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Cortisone acetate</mesh_term>
	<mesh_term>Cortisone</mesh_term>
	<criteria>Participants histologically cytologically document diffuse large Bcell lymphoma ( DLBCL ) must meet least 1 follow risk criterion : Ageadjusted International Prognostic Index ( IPI ) score : 23 Ki67 &gt; = 80 % Histologically , cytologically document activate Bcelllike ( ABC , also know postGCB ) subtype Double hit variant , define vmyc avian myelocytomatosis viral oncogene homolog ( MYC ) gene rearrangement presence Bcell chronic lymphocytic leukemia ( CLL ) /lymphoma ( BCL ) 2 BCL6 gene rearrangement Other aggressive nonDLBCL nonBurkitt nonHodgkin Bcell lymphoma variant define 2008 World Health Organization ( WHO ) classification , include rare CD20 negative Bcell lymphoma ( i.e . plasmablastic lymphoma , primary effusion lymphoma ) also eligible ; grade 3B follicular lymphoma also eligible long one risk criterion meet Participants untreated receive maximum one ( 1 ) cycle combination chemotherapy , include rituximabcontaining regimen , prior eligible ; start previous chemotherapy cycle must occur least 21 day prior begin treatment protocol , cycle count towards total maximum 6 cycle study Documentation HIV infection time prior study entry ; documentation may molecular ( detectable viral ribonucleic acid [ RNA ] polymerase chain reaction [ PCR ] ) , serologic ( positive enzymelinked immunosorbent assay [ ELISA ] positive Western blot ) , federally approve licensed HIV test ; prior documentation HIV seropositivity acceptable All stag disease Measurable nonmeasurable tumor parameter ( ) ; nonmeasurable tumor parameter define bidimensional measurement ( e.g. , gastric marrow involvement ) , follow response diagnostic test gallium , positron emission tomography ( PET ) imaging , and/or bone marrow biopsy Performance status ( PS ) 0 , 1 , 2 per Eastern Cooperative Oncology Group ( ECOG ) performance status scale ( Karnofsky performance score &gt; = 50 % ) Able provide inform consent Total bilirubin = &lt; 1.5 institutional upper limit normal ( ULN ) , unless elevate secondary lymphomatous involvement liver biliary system , due HIV medication ( e.g. , indinavir , tenofovir , atazanavir ) ; direct bilirubin &gt; 1.2 due hepatic involvement tumor initial dose EPOCH drug adjustment Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 2.5 time ULN ( unless elevate due secondary lymphomatous involvement liver ) Negative hepatitis B , infect hepatitis B , receive antihepatitis B therapy ; participant require screen hepatitis B C ; per Infectious Disease Society America ( IDSA ) American Association Study Liver Diseases ( AASD ) guideline , participant show immunity , define lack hepatitis B surface antibody , show evidence chronic infection ( i.e . hepatitis B surface antigen positive [ HBsAg+ ] , hepatitis B core antibody positive [ HBcore+ ] , hepatitis surface antibody negative [ HBsAB ] ) require antihepatitis B therapy , study , order eligible ; participant permit enroll study provide liver function test meet criterion , evidence cirrhosis ; exact hepatitis B therapy discretion infection disease specialist investigator ; however participant present acute hepatitis B show normal transaminase HBsAg+ immunoglobulin ( Ig ) M+ hepatitis core antigen eligible trial enrollment ; participant hepatitis C antibody positive , without positive hepatitis C RNA level , permit enroll study provide liver function test meet criterion , evidence cirrhosis ; participant diagnose hepatitis C le 6 month trial enrollment , consider acute hepatitis C exclude study unless hepatitis ( hep ) C viral load undetectable Creatinine clearance &gt; = 60 mL/min , unless secondary renal involvement lymphoma ; creatinine clearance &lt; 50 mL/min due kidney involvement tumor Granulocytes/absolute neutrophil count ( ANC ) &gt; = 1,000/mm^3 Platelets &gt; = 75,000/mm^3 ( unless parameter abnormal secondary lymphomatous involvement bone marrow ) ; participant must cease colonystimulating factor therapy least 24 hour prior institution cycle 1 chemotherapy Left ventricular ejection fraction ( LVEF ) low institutional limit normal , assessed multiple gate acquisition ( MUGA ) scan echocardiogram within 6 week prior registration Concurrent radiation , without steroid , steroid alone emergency condition secondary lymphoma ( i.e . cord compression , etc . ) permit Female participant must negative pregnancy test within 7 day enter study ; men woman child bear potential must agree use adequate method contraception duration treatment ; woman must avoid pregnancy , men must avoid father child study 6 month follow last study drug treatment Participants antiretroviral regimen receive treatment accordance current International acquire immune deficiency syndrome ( AIDS ) Society guideline ; specific agent discretion investigator use agent currently available expanded access basis allow use experimental antiretroviral agent contain zidovudine ( include Combivir Trizivir ) prohibit ; change highly active antiretroviral therapy ( HAART ) therapy may make medically necessary ( toxicity , failure regimen , etc . ) ; antiretroviral na√Øve participant : participant HAART study entry MUST begin therapy ( utilizing guideline ) AFTER one cycle chemotherapy complete protocol ; change HAART therapy may make medically necessary ( toxicity , failure regimen , etc . ) ; concurrent therapy zidovudine zidovudinecontaining regimen ( include Combivir Trizivir ) prohibit 2 month follow participant 's completion chemotherapy part protocol ; use cobicistat ( e.g. , Tybost ) , cobicistat contain single tablet regimen ( e.g. , Stribild ) prohibit concurrent chemotherapy protocol ; participant take cobicistat cobicistatcontaining single table regimen must switch different agent regimen prior enrollment , remain regimen least 2 month follow treatment discontinuation ; Cobicistat pure potent cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) inhibitor potential increase area curve ( AUC ) CYP3A4 substrates ; therefore , vincristine doxorubicin would potential drug drug interaction ( DDI ) cobicistat since CYP3A4 substrates Participants already receive erythropoietin colonystimulating factor therapy eligible participation , although latter must discontinue least 24 hour prior receive chemotherapy Participants must able swallow oral medication Participants receive one ( 1 ) prior cycle chemotherapy similar cyclophosphamide , doxorubicin hydrochloride , vincristine sulfate , prednisone ( CHOP ) EPOCH without rituximab Absolute CD4 count &lt; 50 cells/ mm^3 Presence second active tumor , nonmelanoma skin cancer , carcinoma situ cervix , Kaposi 's sarcoma ( KS ) require systemic therapy Central nervous system ( CNS ) involvement lymphoma include parenchymal brain spinal cord lymphoma know presence leptomeningeal disease prior registration Participants viral hepatitis meet criterion eligible ; participant present acute hepatitis B include normal transaminase HBsAg+ IgM + hepatitis core antigen eligible ; participant hepatitis B core antibody positive eligible start prophylactic therapy ; hepatitis B viral load confirm negative participant hepatitis B core antibody positive ; participant refuse take antihepatitis B therapy study also exclude ; participant diagnose hepatitis C eligible meet criterion Pregnant woman nurse mother ECOG performance score &gt; = 3 ( Karnofsky performance status [ KPS ] &lt; 50 % ) Expected survival &lt; 2 month Unable comply requirement protocol , unable provide adequate inform consent opinion principal investigator Serious , ongoing , nonmalignant disease infection , opinion investigator and/or sponsor would compromise protocol objective ; participant active opportunistic infection ineligible Major surgery , diagnostic surgery , occur 4 week prior study entry ; splenectomy consider exclusionary major surgery Rituximab therapy within 12 month prior study entry ; participant treat rituximab within 12 month prior study registration eligible give indication treatment aggressive lymphoma Prior cytotoxic chemotherapy radiotherapy lymphoma History cutaneous mucocutaneous reaction , disease past , due cause , severe enough cause hospitalization inability eat drink &gt; 2 day ; exclusion relate longterm possibility severe cutaneous mucocutaneous reaction rituximab might occur increased frequency participant severe skin disease reaction past Use zidovudine cobicistat part HAART regimen ( drug substitution time study entry allow ) Any acute , intercurrent infection may interfere plan protocol treatment ; participant mycobacterium avium exclude study entry ; chronic therapy potentially myelosuppressive agent allow provided entry hematologic criterion meet Myocardial infarction ( MI ) within 6 month prior study entry , New York Heart Association ( NYHA ) class II great heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , clinically significant pericardial disease , electrocardiographic evidence acute ischemic active conduction system abnormalities Participants take valproic acid another histone deacetylase inhibitor least 2 week prior study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>